Mutation-Guided Vaccine Design: A Strategy for Developing Boosting Immunogens for HIV Broadly Neutralizing Antibody Induction
Wiehe, K.; Saunders, K. O.; Stalls, V.; Cain, D. W.; Venkatayogi, S.; Martin Beem, J. S.; Berry, M.; Evangelous, T.; Henderson, R.; Hora, B.; Xia, S.-M.; Jiang, C.; Newman, A.; Bowman, C.; Lu, X.; Bryan, M. E.; Bal, J.; Sanzone, A.; Chen, H.; Eaton, A.; Tomai, M. A.; Fox, C. B.; Tam, Y.; Barbosa, C.; Bonsignori, M.; Muramatsu, H.; Alam, M.; Montefiori, D.; Williams, W. B.; Pardi, N.; Tian, M.; Weissman, D.; Alt, F. W.; Acharya, P.; Haynes, B. F.
Show abstract
A major goal of HIV-1 vaccine development is induction of broadly neutralizing antibodies (bnAbs). While success has been achieved in initiating bnAb B cell lineages, design of boosting immunogens that select for bnAb B cell receptors with improbable mutations required for bnAb affinity maturation remains difficult. Here we demonstrate a process for designing boosting immunogens for a V3-glycan bnAb B cell lineage. The immunogens induced affinity-matured antibodies by selecting for functional improbable mutations in bnAb precursor knock-in mice. Moreover, we show similar success in prime and boosting with nucleoside-modified mRNA-encoded HIV-1 envelope trimer immunogens, with improved selection by mRNA immunogens of improbable mutations required for bnAb binding to key envelope glycans. These results demonstrate the ability of both protein and mRNA prime-boost immunogens for selection of rare B cell lineage intermediates with neutralizing breadth after bnAb precursor expansion, a key proof-of concept and milestone towards development of an HIV vaccine. One-Sentence SummaryA vaccine strategy for selecting key rare antibody mutations is shown to induce HIV broadly neutralizing antibodies in mice.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease 97%
- Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants 97%
- A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants 96%
Similar papers in this journal
Similar papers in this journal
- Vaccine Elicitation of HIV-1 Neutralizing Antibodies Against Both V2 Apex and Fusion Peptide in Rhesus Macaques 97%
- Transient glycan-shield reduction induces CD4-binding site broadly neutralizing antibodies in SHIV-infected macaques 97%
- Clonal Expansion and Diversification of Germinal Center and Memory B Cell Responses to Booster Immunization in Primates 96%
Similar papers in this journal
- Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques 98%
- Antigen-agnostic identification of poxvirus broadly neutralizing antibodies targeting OPG153 97%
- The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD 97%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.